Aspira Women's Health Inc.(AWHL.US)

Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company’s products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1’s high sensitivity; and OvaWatch, a assist in the initial and periodic clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass. It is also developing OVAinform, a multi-marker test that combines serum proteins, clinical data, and miRNA for assessing the risk of ovarian cancer in women with an adnexal mass. The company also operates Aspira Labs, a laboratory that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease.